Skip to main content

Table 2 Demographic and clinical characteristics of the patients from whom CSF samples were studied. Case (AD); control (C); p (Student’s t-test)

From: proBDNF is modified by advanced glycation end products in Alzheimer’s disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing

  Case(n = 15) C(n = 15) P
Male 4 (26.7%) 5 (33.3%) 0.7
Years 73.5 ± 12,1 70.5 ± 7,1 0.6
Age schooling 11.3 ± 5,0 11.3 ± 2,2 0.2
MMSE 19,1 ± 6,0 28,1 ± 1,8 0
Family history
Presenilin AD 2(13.3%) 0(0%) 0.14
EA > 65 years 3(20.0%) 5(33.3%) 0.4
Pathological history
Hypertension 6(40%) 8(53%) 0.46
Diabetes 3(20.0%) 2(13.3%) 0.6
Hypercolesterolemia 2(13.3%) 7(46.7%) 0.04
Depression 2(13.3%) 7(46.7%) 0.04
CSF AD Biomarkers pg/ml pg/ml  
Amyloid β 386,128 856 ± 204 0
Total Tau 615 ± 270 281 ± 103 0.01
PhosphoTau 85 ± 28 55 ± 18 0